Antibodies, Monoclonal, Humanized Concept

subject area of

• 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis  Journal Articles
• 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis  Journal Articles
• A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies  Journal Articles
• A Case of Successful Pembrolizumab Rechallenge in a Patient with Non-Small-Cell Lung Cancer and Grade 3 Dermatomyositis  Journal Articles
• A Decade of Respiratory Syncytial Virus Epidemiology and Prophylaxis: Translating Evidence into Everyday Clinical Practice  Journal Articles
• A Monoclonal Antibody Against β1 Integrin Inhibits Proliferation and Increases Survival in an Orthotopic Model of High-Grade Meningioma  Journal Articles
• A Phase 1 Study of Mapatumumab (Fully Human Monoclonal Antibody to TRAIL-R1) in Patients with Advanced Solid Malignancies  Journal Articles
• A Phase II Study of PF-03446962 in Patients with Advanced Malignant Pleural Mesothelioma. CCTG Trial IND.207  Journal Articles
• A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS)  Journal Articles
• A fatal case of Pneumocystis jirovecii pneumonia in a breast cancer patient receiving weekly paclitaxel and trastuzumab  Journal Articles
• A halotyrosine antibody that detects increased protein modifications in asthma patients  Journal Articles
• A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial  Journal Articles
• A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial*  Journal Articles
• A meta-analysis of the effect of antibody therapy for the prevention of severe respiratory syncytial virus infection  Journal Articles
• A new cost-utility analysis assessing risk factor-guided prophylaxis with palivizumab for the prevention of severe respiratory syncytial virus infection in Italian infants born at 29–35 weeks’ gestational age  Journal Articles
• A new frontier in treatment of advanced melanoma: Redefining clinical management in the era of immune checkpoint inhibitors  Journal Articles
• A phase IB study of durvalumab with or without tremelimumab and platinum-doublet chemotherapy in advanced solid tumours: Canadian Cancer Trials Group Study IND226  Journal Articles
• A pilot randomised clinical trial of mepolizumab in COPD with eosinophilic bronchitis  Journal Articles
• A randomized, placebo-controlled trial of canakinumab in patients with peripheral artery disease.  Journal Articles
• A real‐world, observational study of erenumab for migraine prevention in Canadian patients  Journal Articles
• A review of cost–effectiveness of palivizumab for respiratory syncytial virus  Journal Articles
• A systematic review and expert Delphi Consensus recommendation on the use of vaccines in patients receiving dupilumab: A position paper of the American College of Allergy, Asthma and Immunology  Journal Articles
• A systematic review of recent randomized controlled trials for palmoplantar pustulosis.  Journal Articles
• Abelacimab for Prevention of Venous Thromboembolism  Journal Articles
• Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation.  Journal Articles
• Accurately Assessing the Expected Impact of Universal First Respiratory Syncytial Virus (RSV) Season Immunization With Nirsevimab Against RSV-Related Outcomes and Costs Among All US Infants  Journal Articles
• Adalimumab for Treatment of Moderate to Severe Chronic Plaque Psoriasis of the Hands and Feet  Journal Articles
• Adalimumab in the Treatment of Psoriasis: Pooled Efficacy and Safety Results from Three Pivotal Studies  Journal Articles
• Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naïve to anti-TNF therapy: An indirect treatment comparison meta-analysis  Journal Articles
• Adjuvant trastuzumab for HER2-positive breast cancer  Journal Articles
• Advancing Novel Molecular Imaging Agents from Preclinical Studies to First-in-Humans Phase I Clinical Trials in Academia—A Roadmap for Overcoming Perceived Barriers  Journal Articles
• Adverse Gastrointestinal Events with Intravitreal Injection of Vascular Endothelial Growth Factor Inhibitors: Nested Case–Control Study  Journal Articles
• Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study  Journal Articles
• Age affects drug survival rates of interleukin (IL)‐17 and IL‐23 inhibitors in patients with plaque psoriasis: Results from a retrospective, multicentric, multi‐country, cohort study  Journal Articles
• Alemtuzumab and CHOP Chemotherapy for the Treatment of Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Center Phase I Study  Journal Articles
• Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial  Journal Articles
• Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome  Journal Articles
• An Open Letter to Health Canada  Journal Articles
• An open-label, prospective cohort pilot study to evaluate the efficacy and safety of etanercept in the treatment of moderate to severe plaque psoriasis in patients who have not had an adequate response to adalimumab.  Journal Articles
• Anti-Aβ agents for mild to moderate Alzheimer's disease: systematic review and meta-analysis  Journal Articles
• Anti-TNFα therapy in immune-mediated subfertility: State of the art  Journal Articles
• Anti-cytokine targeted therapies for ANCA-associated vasculitis  Journal Articles
• Antiangiogenic Therapies in Non-Small-Cell Lung Cancer  Journal Articles
• Anticoagulation with osocimab in patients with kidney failure undergoing hemodialysis: a randomized phase 2 trial  Journal Articles
• Antidotes for Novel Oral Anticoagulants  Journal Articles
• Anti–IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics  Journal Articles
• Anti–Interleukin-5 Monoclonal Antibody to Treat Severe Eosinophilic Asthma  Journal Articles
• Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.  Journal Articles
• Are late preterm infants as susceptible to RSV infection as full term infants?  Journal Articles
• Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial  Journal Articles
• Asthma Control, Airway Mucus, and 129Xe MRI Ventilation After a Single Benralizumab Dose  Journal Articles
• Asthma exacerbations on benralizumab are largely non‐eosinophilic  Journal Articles
• Asthma that is unresponsive to usual care  Journal Articles
• Atypical Femoral Fractures: A Teaching Perspective  Journal Articles
• BDNF/TrkB Content and Interaction with Gastrin-Releasing Peptide Receptor Blockade in Colorectal Cancer  Journal Articles
• Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial  Journal Articles
• Belantamab mafodotin, pomalidomide, and dexamethasone for triple class exposed/refractory relapsed multiple myeloma: a subgroup analysis of the ALGONQUIN trial.  Journal Articles
• Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSErve Canada Study  Journal Articles
• Bell's palsy in a patient receiving adalimumab for Crohn's disease  Journal Articles
• Benralizumab attenuates airway eosinophilia in prednisone-dependent asthma  Journal Articles
• Benralizumab for Prednisone-Dependent Eosinophilic Asthma Associated With Novel STAT3 Loss of Function Mutation  Journal Articles
• Benralizumab for allergic asthma: a randomised, double-blind, placebo-controlled, trial  Journal Articles
• Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme  Journal Articles
• Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis  Journal Articles
• Benralizumab's anti-eosinophil efficacy may be decreased by impaired NK cell activity  Journal Articles
• Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial  Journal Articles
• Bevacizumab in advanced lung cancer: in search of the right drug for the right patient.  Journal Articles
• Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial  Journal Articles
• Bimekizumab: The First Dual Inhibitor of Interleukin (IL)-17A and IL-17F for the Treatment of Psoriatic Disease and Ankylosing Spondylitis  Journal Articles
• Biologic Therapies for Chronic Obstructive Pulmonary Disease: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.  Journal Articles
• Biologic survival.  Journal Articles
• Biosimilars for psoriasis: clinical studies to determine similarity  Journal Articles
• Bleeding Complications and Management on anticoagulant therapy  Journal Articles
• Briakinumab  Journal Articles
• Brodalumab success in patients with moderate-to-severe psoriasis who failed previous interleukin-17A inhibitors  Journal Articles
• CARESS: The Canadian Registry of Palivizumab  Journal Articles
• CD25 Blockade Delays Regulatory T Cell Reconstitution and Does Not Prevent Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation  Journal Articles
• COMMENTARY: Should Anti‐TNF‐α Therapy be Offered to Patients with Infertility and Recurrent Spontaneous Abortion?*  Journal Articles
• Campath-1H Treatment of T-Cell Prolymphocytic Leukemia in Patients for Whom at Least One Prior Chemotherapy Regimen Has Failed  Journal Articles
• Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn’s Disease  Journal Articles
• Canadian Multicenter Project on Standardization of Programmed Death-Ligand 1 Immunohistochemistry 22C3 Laboratory-Developed Tests for Pembrolizumab Therapy in NSCLC  Journal Articles
• Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-α drugs for refractory Crohn's disease  Journal Articles
• Canadian expert consensus: optimal treatment of neovascular age-related macular degeneration  Journal Articles
• Canakinumab After Electrical Cardioversion in Patients With Persistent Atrial Fibrillation  Journal Articles
• Carboplatin and Pembrolizumab Chemoimmunotherapy Achieves Remission in Recurrent, Metastatic Sebaceous Carcinoma.  Journal Articles
• Cardiac Troponin Cutoffs: The Importance of Assay Sensitivity and the Patient Population  Journal Articles
• Cardiac and Inflammation Biomarker Profile after Initiation of Adjuvant Trastuzumab Therapy  Journal Articles
• Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients  Journal Articles
• Cetuximab in Metastatic Squamous Cell Cancer of the Skin: A Swiss Case Series  Journal Articles
• Changing costs and the impact on RSV prophylaxis  Journal Articles
• Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase 3 CLEAR Study  Journal Articles
• Clinical Efficacy and Safety of Denosumab in Postmenopausal Women with Low Bone Mineral Density and Osteoporosis: A Meta-Analysis  Journal Articles
• Clinical Implications of Reversal Agents for Direct Oral Anticoagulants  Journal Articles
• Comment and reply on: The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32–35 weeks: a Canadian-based analysis  Journal Articles
• Comparative Effectiveness of Atezolizumab, Nivolumab, and Docetaxel in Patients With Previously Treated Non–Small Cell Lung Cancer  Journal Articles
• Comparative Efficacy for Infliximab Vs Vedolizumab in Biologic Naive Ulcerative Colitis  Journal Articles
• Comparative assessment of subretinal hyper-reflective material in patients treated with brolucizumab versus aflibercept in HAWK and HARRIER  Journal Articles
• Comparing the efficacy of vedolizumab between males and females: a post-hoc analysis of GEMINI-1 and VARSITY  Journal Articles
• Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials  Journal Articles
• Comparison of the Cost of Hospitalization for Respiratory Syncytial Virus Disease Versus Palivizumab Prophylaxis in Canadian Inuit Infants  Journal Articles
• Concizumab prophylaxis in people with haemophilia A or haemophilia B without inhibitors (explorer8): a prospective, multicentre, open-label, randomised, phase 3a trial.  Journal Articles
• Connective-Tissue Growth Factor Contributes to TGF-β1–induced Lung Fibrosis  Journal Articles
• Cost per remission and cost per response with infliximab, adalimumab, and golimumab for the treatment of moderately-to-severely active ulcerative colitis  Journal Articles
• Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective  Journal Articles
• Cost-effectiveness analysis of secukinumab in ankylosing spondylitis from the Canadian perspective  Journal Articles
• Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis  Journal Articles
• Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporosis in Canada  Journal Articles
• Cost-effectiveness of respiratory syncytial virus prophylaxis in premature infants less than 32 weeks gestational age in Turkey.  Journal Articles
• Cost-effectiveness of wastewater and environmental monitoring of respiratory syncytial virus to guide universal infant immunoprophylaxis in Canada.  Journal Articles
• Current strategies in the prevention of respiratory syncytial virus disease  Journal Articles
• Cytokine-Based Therapy in Psoriasis  Journal Articles
• Dabigatran Reversal With Idarucizumab in Patients Requiring Urgent Surgery  Journal Articles
• Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment  Journal Articles
• Dabigatran Reversal with Idarucizumab  Journal Articles
• Dabigatran reversal by idarucizumab in the setting of intracranial hemorrhage: A systematic review of the literature  Journal Articles
• Decision Support Tool Identifies Ulcerative Colitis Patients Most Likely to Achieve Remission With Vedolizumab vs Adalimumab  Journal Articles
• Denosumab Treatment in Postmenopausal Women with Osteoporosis Does Not Interfere with Fracture-Healing  Journal Articles
• Denosumab treatment for fibrous dysplasia  Journal Articles
• Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis  Journal Articles
• Denosumab: mechanism of action and clinical outcomes  Journal Articles
• Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran  Journal Articles
• Detection of Pulmonary Emboli With ^99mTc-Labeled Anti–D-dimer (DI-80B3)Fab′ Fragments (ThromboView)  Journal Articles
• Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn’s Disease  Journal Articles
• Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus  Journal Articles
• Diretrizes Brasileiras para o tratamento farmacológico de pacientes hospitalizados com COVID-19  Journal Articles
• Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial  Journal Articles
• Does prophylaxis with palivizumab reduce hospitalisation rates for respiratory‐syncytial‐virus‐related infection in cystic fibrosis children less than 2 years of age?  Journal Articles
• Dose-Ranging and Cohort-Expansion Study of Monalizumab (IPH2201) in Patients with Advanced Gynecologic Malignancies: A Trial of the Canadian Cancer Trials Group (CCTG): IND221  Journal Articles
• Dual-Agent Molecular Targeting of the ErbB2 Receptor: Killing One Bird With Two Stones  Journal Articles
• Dupilumab, severe asthma airway responses, and SARS‐CoV‐2 serology  Journal Articles
• Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial  Journal Articles
• Early and late changes in markers of aortic stiffness with breast cancer therapy  Journal Articles
• Economic Evaluation of Bevacizumab for the First-Line Treatment of Newly Diagnosed Glioblastoma Multiforme  Journal Articles
• Eculizumab for treatment of asthma  Journal Articles
• Effect of Alirocumab on Mortality After Acute Coronary Syndromes  Journal Articles
• Effect of Brolucizumab and Aflibercept on the Maximum Thickness of Pigment Epithelial Detachments and Sub-Retinal Pigment Epithelium Fluid in HAWK and HARRIER.  Journal Articles
• Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer  Journal Articles
• Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis  Journal Articles
• Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia  Journal Articles
• Effect of Herceptin on the development and progression of skeletal metastases in a xenograft model of human breast cancer  Journal Articles
• Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty  Journal Articles
• Effect of dupilumab on sputum eosinophils in patients with moderate‐to‐severe asthma  Journal Articles
• Effect of secukinumab on quality of life and psoriasis-related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52-week study  Journal Articles
• Effectiveness at 1 Year of Monthly versus Variable-Dosing Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-related Macular Degeneration  Journal Articles
• Effects of Dupilumab on Mucus Plugging and Ventilation Defects in Patients with Moderate-to-Severe Asthma: A Randomized, Double-Blind, Placebo-Controlled Trial  Journal Articles
• Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial  Journal Articles
• Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial  Journal Articles
• Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia  Journal Articles
• Effects of therapies for Ebola virus disease: a systematic review and network meta-analysis  Journal Articles
• Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma  Journal Articles
• Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double‐Blind, Placebo‐Controlled Trials  Journal Articles
• Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance  Journal Articles
• Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study  Journal Articles
• Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses  Journal Articles
• Efficacy and safety of reslizumab in patients with moderate to severe eosinophilic asthma  Journal Articles
• Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines ‐ recommendations on the use of biologicals in severe asthma  Journal Articles
• Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines ‐ recommendations on the use of biologicals in severe asthma  Journal Articles
• Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines—Recommendations on the use of biologicals in severe asthma  Journal Articles
• Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase 3, randomised, double-blind, parallel trials  Journal Articles
• Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial  Journal Articles
• Efficacy of Biological Therapies in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis  Journal Articles
• Efficacy of Biologics in Patients with Allergic Bronchopulmonary Aspergillosis: A Systematic Review and Meta-Analysis  Journal Articles
• Efficacy of Intravenous Reslizumab in Oral Corticosteroid–Dependent Asthma  Journal Articles
• Emerging monoclonal antibodies as targeted innovative therapeutic approaches to asthma  Journal Articles
• Emerging therapeutic options for the treatment of patients with symptomatic asthma  Journal Articles
• Emicizumab and thrombosis: The story so far  Journal Articles
• Emicizumab state‐of‐the‐art update  Journal Articles
• European oncologists' preferences for the management of breast cancer: case presentations and expert commentary  Journal Articles
• Evaluating in vivo effectiveness of sotrovimab for the treatment of Omicron subvariant BA.2 versus BA.1: a multicentre, retrospective cohort study  Journal Articles
• Evolocumab in HIV-Infected Patients With Dyslipidemia  Journal Articles
• Exacerbations of Severe Asthma While on Anti–IL-5 Biologics  Journal Articles
• First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial.  Journal Articles
• Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma  Journal Articles
• Fractionation of bovine serum albumin and monoclonal antibody alemtuzumab using carrier phase ultrafiltration  Journal Articles
• Garadacimab for hereditary angioedema attack prevention: long-term efficacy, quality of life, and safety data from a phase 2, randomised, open-label extension study  Journal Articles
• Generic immunosuppression in solid organ transplantation: systematic review and meta-analysis  Journal Articles
• Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer  Journal Articles
• Granulocyte–macrophage colony‐stimulating factor ( GM ‐ CSF ) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti‐ GM ‐ CSF monoclonal antibody  Journal Articles
• Guselkumab dosing interval optimization in adult patients with psoriasis: A retrospective, multicenter case series  Journal Articles
• HER2 Testing in a Population-Based Study of Patients With Metastatic Breast Cancer Treated With Trastuzumab  Journal Articles
• Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD™ study  Journal Articles
• Hematopoietic Processes in Eosinophilic Asthma  Journal Articles
• Herceptest: Her2 expression and gene amplification in non-small cell lung cancer  Journal Articles
• High risk for RSV bronchiolitis in late preterms and selected infants affected by rare disorders: a dilemma of specific prevention  Journal Articles
• Higher vedolizumab serum levels do not increase the risk of adverse events in patients with inflammatory bowel disease  Journal Articles
• Histopathologic features of biologic therapy nonresponders in chronic rhinosinusitis with nasal polyposis.  Journal Articles
• Hospitalization for Respiratory Syncytial Virus Illness in Down Syndrome Following Prophylaxis With Palivizumab  Journal Articles
• How can we reverse bleeding in patients on direct oral anticoagulants?  Journal Articles
• Idarucizumab  Journal Articles
• Idarucizumab for Dabigatran Reversal  Journal Articles
• Idarucizumab for Dabigatran Reversal — Full Cohort Analysis  Journal Articles
• Idarucizumab for dabigatran overdose  Journal Articles
• Identifying and Ensuring Optimal Care for All Children at Risk of Developing Serious Respiratory Syncytial Virus Disease: A Canadian Nurses’ Perspective  Journal Articles
• Immune Checkpoint Inhibitors for Patients With Advanced Non–Small-Cell Lung Cancer: A Systematic Review  Journal Articles
• Immune Thrombocytopenia Associated with Efalizumab Therapy for Psoriasis  Journal Articles
• Immune response to pneumococcus and tetanus toxoid in patients with moderate-to-severe psoriasis following long-term ustekinumab use.  Journal Articles
• Immunotherapies in Dermatologic Disorders  Journal Articles
• Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis  Journal Articles
• Improvement in health utility among patients with rheumatoid arthritis treated with adalimumab (a human anti-TNF monoclonal antibody) plus methotrexate  Journal Articles
• In COVID-19, tocilizumab reduces all-cause mortality at 28 d  Journal Articles
• In patients hospitalized for COVID-19, tocilizumab reduces mortality at 28 d  Journal Articles
• In patients with rheumatoid arthritis, bDMARD therapy was not associated with malignant neoplasms  Journal Articles
• Incidence and prognosis of COVID-19 in patients with atopic diseases on dupilumab: a multicentre retrospective cohort study  Journal Articles
• Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule Inhibitors  Journal Articles
• Indirect comparison of the efficacy of cetuximab and cisplatin in squamous cell carcinoma of the head and neck  Journal Articles
• Indirect comparison: relative risk fallacies and odds solution  Journal Articles
• Integrated safety analysis of treatment‐emergent eczematous reactions in patients with moderate‐to‐severe psoriasis treated with ixekizumab, etanercept and ustekinumab  Journal Articles
• Interleukin-6 receptor blockade in patients with COVID-19: placing clinical trials into context  Journal Articles
• Interventions for treatment of COVID-19: Second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project)  Journal Articles
• Is tezepelumab more than just an anti-eosinophil drug?  Journal Articles
• Ixekizumab improves patient-reported outcomes in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitors: SPIRIT-P2 results to 52 weeks.  Journal Articles
• JAVELIN: avelumab another spear to fight urothelial carcinoma  Journal Articles
• KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation  Journal Articles
• LDP-02 (Millenium).  Journal Articles
• Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31  Journal Articles
• Left and right ventricular effects of anthracycline and trastuzumab chemotherapy: A prospective study using novel cardiac imaging and biochemical markers  Journal Articles
• Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study.  Journal Articles
• Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study  Journal Articles
• Letter: comparative safety and efficacy of infliximab vs. adalimumab in Crohn's disease – should one consider disease location? Authors’ reply  Journal Articles
• Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol  Journal Articles
• Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17  Journal Articles
• Long-Term Outcomes of Early vs Delayed Responders to Vedolizumab and Adalimumab: A Post Hoc Analysis of the VARSITY Study  Journal Articles
• Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial  Journal Articles
• Long-term safety and efficacy of garadacimab for preventing hereditary angioedema attacks: Phase 3 open-label extension study.  Journal Articles
• Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes  Journal Articles
• Lower-dose emicizumab prophylaxis: can less be more?  Journal Articles
• Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials  Conferences
• Managing drug shortages during a pandemic: tocilizumab and COVID-19  Journal Articles
• Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trial  Journal Articles
• Mepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia  Journal Articles
• Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial  Journal Articles
• Metastatic renal cell cancer treatments: An indirect comparison meta-analysis  Journal Articles
• Meta‐analysis: peri‐operative anti‐TNFα treatment and post‐operative complications in patients with inflammatory bowel disease  Journal Articles
• Methodology for the international working group clinical practice guidelines on X-linked hypophosphatemia in children and adults.  Journal Articles
• MicroRNA Signature in Metastatic Colorectal Cancer Patients Treated With Anti-EGFR Monoclonal Antibodies  Journal Articles
• NCIC CTG IND.190 Phase I Trial of Dalotuzumab (MK-0646) in Combination with Cisplatin and Etoposide in Extensive-Stage Small-Cell Lung Cancer  Journal Articles
• NOAC monitoring, reversal agents, and post-approval safety and effectiveness evaluation: A cardiac safety research consortium think tank  Journal Articles
• Nail Psoriasis and Biologics  Journal Articles
• Nephrocalcinosis and kidney function in children and adults with X-linked hypophosphatemia: baseline results from a large longitudinal study.  Journal Articles
• Nitric oxide in exhaled breath is poorly correlated to sputum eosinophils in patients with prednisone-dependent asthma  Journal Articles
• Nomogram to Assess the Survival Benefit of New Salvage Agents for Metastatic Urothelial Carcinoma in the Era of Immunotherapy  Journal Articles
• Normalisation of MRI ventilation heterogeneity in severe asthma by dupilumab  Journal Articles
• Norms-based assessment of patient-reported outcomes associated with adalimumab monotherapy in patients with ankylosing spondylitis.  Journal Articles
• Novel method for differentiation between Trastuzumab and host adaptive response  Journal Articles
• Novel oral anticoagulants and reversal agents: Considerations for clinical development  Journal Articles
• Novel targeted therapies for eosinophilic disorders  Journal Articles
• Off-Label High-Dose Secukinumab for the Treatment of Moderate-to-Severe Psoriasis  Journal Articles
• Omalizumab and the immune system: an overview of preclinical and clinical data  Journal Articles
• Omalizumab for asthma in adults and children  Journal Articles
• Open: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium  Journal Articles
• Optimizing Survival and the Changing Landscape of Targeted Therapy for Intermediate and Advanced Hepatocellular Carcinoma: A Systematic Review  Journal Articles
• Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma  Journal Articles
• Outcomes of Patients With Prior Biologic Intolerance Are Better Than Those With Biologic Failure in Clinical Trials of Inflammatory Bowel Disease.  Journal Articles
• Overstated Conclusions of a Pooled Analysis of Bevacizumab in Colon Cancer  Journal Articles
• P-Selectin de-ACTIVation in COVID-19: What Have We Learned?  Journal Articles
• Pain-Related Quality of Life Outcomes in People With Haemophilia A Receiving Emicizumab: A Post Hoc Analysis of the HAVEN 1, 3 and 4 and STASEY Studies.  Journal Articles
• Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes  Journal Articles
• Palivizumab prophylaxis for respiratory syncytial virus in infants with cystic fibrosis: is there a need?  Journal Articles
• Parameter scanning ultrafiltration: Rapid optimisation of protein separation  Journal Articles
• Patient outcomes after anti TNF-α drugs for Crohn’s disease  Journal Articles
• Pegylated Liposomal Doxorubicin and Trastuzumab in HER-2 Overexpressing Metastatic Breast Cancer: A Multicenter Phase II Trial  Conferences
• Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial  Journal Articles
• Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial  Conferences
• Pembrolizumab-induced immune-related sclerosing cholangitis  Journal Articles
• Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study  Journal Articles
• Perspectives on shorter durations of anti-HER2 therapy in early-stage HER2-positive breast cancer: a patient survey  Journal Articles
• Pertuzumab and trastuzumab infusion related cytokine release syndrome in a chemotherapy naive patient with metastatic breast cancer  Journal Articles
• Pexelizumab Does Not “Complement” Percutaneous Coronary Intervention in Patients With ST-Elevation Myocardial Infarction  Journal Articles
• Pharmacokinetic implications of dosing emicizumab based on vial size: A simulation study  Journal Articles
• Pharmacokinetics, Safety, and Efficacy of Trastuzumab Administered Every Three Weeks in Combination With Paclitaxel  Journal Articles
• Pharmacologic insights into the future of trastuzumab.  Conferences
• Pharmacologic management of neovascular age-related macular degeneration: systematic review of economic evidence and primary economic evaluation  Journal Articles
• Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia  Conferences
• Phase II Study of Ganitumab, a Fully Human Anti–Type-1 Insulin-Like Growth Factor Receptor Antibody, in Patients With Metastatic Ewing Family Tumors or Desmoplastic Small Round Cell Tumors  Journal Articles
• Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I  Journal Articles
• Plant-Produced Trastuzumab Inhibits the Growth of HER2 Positive Cancer Cells  Journal Articles
• Pointed Progress in Second-Line Advanced Non–Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition  Journal Articles
• Polymorphisms and Clinical Outcome in Recurrent Ovarian Cancer Treated with Cyclophosphamide and Bevacizumab  Journal Articles
• Practical Understanding of Mean Percent Psoriasis Area and Severity Index Reduction for Biologics  Journal Articles
• Pre-operative bevacizumab, capecitabine, oxaliplatin and radiation among patients with locally advanced or low rectal cancer: A phase II trial  Journal Articles
• Preclinical pharmacokinetics, biodistribution, radiation dosimetry and acute toxicity studies required for regulatory approval of a Clinical Trial Application for a Phase I/II clinical trial of 111In-BzDTPA-pertuzumab  Journal Articles
• Predictors of Immunotherapy-Induced Immune-Related Adverse Events  Journal Articles
• Predictors of histologic response to mepolizumab in pediatric eosinophilic esophagitis  Journal Articles
• Preparative separation of monoclonal antibody aggregates by cation-exchange laterally-fed membrane chromatography  Journal Articles
• Prevalence of endoscopic improvement and remission according to patient‐reported outcomes in ulcerative colitis  Journal Articles
• Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma  Journal Articles
• Prospective Cost-Effectiveness Analysis of Cetuximab in Metastatic Colorectal Cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 Trial  Journal Articles
• Radiosensitization of glioma cells by modulation of Met signalling with the hepatocyte growth factor neutralizing antibody, AMG102  Journal Articles
• Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck  Journal Articles
• Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival  Journal Articles
• Randomized Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration-Resistant Prostate Cancer.  Journal Articles
• Randomized Phase II Study of Gemcitabine Plus Cisplatin or Carboplatin, With or Without Cetuximab, As First-Line Therapy for Patients With Advanced or Metastatic Non–Small-Cell Lung Cancer  Conferences
• Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer  Journal Articles
• Randomized phase 2 trial comparing JNJ‐9375, a thrombin‐directed antibody, with apixaban for prevention of venous thrombosis  Journal Articles
• Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy  Journal Articles
• Ranibizumab and the eye  Journal Articles
• Rebuttal: palivizumab for the prevention of respiratory syncytial virus infection.  Journal Articles
• Reslizumab for Poorly Controlled, Eosinophilic Asthma  Journal Articles
• Respiratory Syncytial Virus Prophylaxis in Down Syndrome: A Prospective Cohort Study  Journal Articles
• Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations  Journal Articles
• Respiratory syncytial virus prophylaxis in children with cardiac disease: a retrospective single-centre study  Journal Articles
• Respiratory-Related Hospitalizations following Prophylaxis in the Canadian Registry for Palivizumab (2005–2012) Compared to Other International Registries  Journal Articles
• Reversal agents for non-vitamin K antagonist oral anticoagulants  Journal Articles
• Reversal of Direct Oral Anticoagulants: Current Status and Future Directions  Journal Articles
• Reversal of direct oral anticoagulants: Guidance from the Anticoagulation Forum  Journal Articles
• Reversal of direct oral anticoagulants: a practical approach  Journal Articles
• Reversal of direct oral anticoagulants: guidance from the SSC of the ISTH  Journal Articles
• Review of Systemic Treatment Options for Adult Atopic Dermatitis  Journal Articles
• Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes  Journal Articles
• Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33–35 completed weeks’ gestational age in Canada  Journal Articles
• Role of Biologics in Asthma  Journal Articles
• Role of Thymic Stromal Lymphopoietin in the Pathophysiology of Asthma and Clinical and Biological Effects of Blockade With Tezepelumab  Journal Articles
• Role of local eosinophilopoietic processes in the development of airway eosinophilia in prednisone‐dependent severe asthma  Journal Articles
• Safety and effectiveness of adalimumab in a clinical setting that reflects Canadian standard of care for the treatment of rheumatoid arthritis (RA): Results from the CanACT study  Journal Articles
• Safety and efficacy analysis of pembrolizumab dosing patterns in patients with advanced melanoma and non-small cell lung cancer  Journal Articles
• Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial  Journal Articles
• Safety of Treatment of Metastatic Breast Cancer With Trastuzumab Beyond Disease Progression  Journal Articles
• Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation.  Journal Articles
• Sample sizes for clinical trials using sputum eosinophils as a primary outcome  Journal Articles
• Seasonal Respiratory Syncytial Virus Prophylaxis Based on Predetermined Dates Versus Regional Surveillance Data  Journal Articles
• Second‐line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real‐world eligibility for cabozantinib, regorafenib, and ramucirumab  Journal Articles
• Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE)  Journal Articles
• Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment: Results from the CLEAR study  Journal Articles
• Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials  Journal Articles
• Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study  Journal Articles
• Separation of monoclonal antibody alemtuzumab monomer and dimers using ultrafiltration  Journal Articles
• Serum amlyoid A: An inflammatory adipokine mediating postburn outcomes  Journal Articles
• Specific antidotes for bleeding associated with direct oral anticoagulants  Journal Articles
• Sputum Hyaluronan and Versican in Severe Eosinophilic Asthma  Journal Articles
• Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial  Journal Articles
• Stroke Rates after Introduction of Vascular Endothelial Growth Factor Inhibitors for Macular Degeneration: A Time Series Analysis  Journal Articles
• Successful treatment of recurrent pleural and pericardial effusions with tocilizumab in a patient with systemic lupus erythematous  Journal Articles
• Switching biologics in chronic rhinosinusitis with nasal polyps: A multicenter Canadian experience.  Journal Articles
• Systematic Review and Meta-Analysis: Preoperative Vedolizumab Treatment and Postoperative Complications in Patients with Inflammatory Bowel Disease  Journal Articles
• Systematic Review: Efficacy of Medical Therapy on Outcomes Important to Adult Patients With X-Linked Hypophosphatemia.  Journal Articles
• Systematic Review: Efficacy of Medical Therapy on Outcomes Important to Pediatric Patients With X-Linked Hypophosphatemia.  Journal Articles
• Systematic review and meta‐analysis: Safety of vedolizumab during pregnancy in patients with inflammatory bowel disease  Journal Articles
• Systemic Immunomodulatory Treatments for Patients With Atopic Dermatitis  Journal Articles
• Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update  Journal Articles
• Targeted therapy for metastatic renal cell carcinoma  Journal Articles
• Targeting apoptosis: preclinical and early clinical experience with mapatumumab, an agonist monoclonal antibody targeting TRAIL-R1  Journal Articles
• Targeting the epidermal growth factor receptor in non-small-cell lung cancer: Who, which, when, and how?  Journal Articles
• Tezepelumab in patients with allergic and eosinophilic asthma  Journal Articles
• The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma  Journal Articles
• The Demise of Anti–IL-5 for Asthma, or Not  Journal Articles
• The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V—Special Situations  Journal Articles
• The Pediatric Investigators Collaborative Network on Infections in Canada Study of Predictors of Hospitalization for Respiratory Syncytial Virus Infection for Infants Born at 33 Through 35 Completed Weeks of Gestation  Journal Articles
• The Real-World Effectiveness and Safety of Vedolizumab for Moderate–Severe Crohn’s Disease: Results From the US VICTORY Consortium  Journal Articles
• The Real‐Life Effectiveness of Palivizumab for Reducing Hospital Admissions for Respiratory Syncytial Virus in Infants Residing in Nunavut  Journal Articles
• The Role of Omalizumab in the Treatment of Severe Allergic Asthma  Journal Articles
• The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial  Journal Articles
• The cost effectiveness of palivizumab in congenital heart disease: a review of the current evidence  Journal Articles
• The cost effectiveness of palivizumab in term Inuit infants in the Eastern Canadian Arctic  Journal Articles
• The cost effectiveness of palivizumab: a systematic review of the evidence  Journal Articles
• The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32–35 weeks: a Canadian-based analysis  Journal Articles
• The effect of emicizumab prophylaxis on long‐term, self‐reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies  Journal Articles
• The effects of an anti-CD11a mAb, efalizumab, on allergen-induced airway responses and airway inflammation in subjects with atopic asthma  Journal Articles
• The efficacy and toxicity of immune checkpoint inhibitors in a real-world older patient population  Journal Articles
• The impact of prophylaxis on paediatric intensive care unit admissions for RSV infection: a retrospective, single-centre study  Journal Articles
• Therapeutic efficacy of an alpha-particle emitter labeled anti-GD2 humanized antibody against osteosarcoma—a proof of concept study  Journal Articles
• Thrombotic microangiopathy in the course of catastrophic antiphospholipid syndrome successfully treated with eculizumab: case report and systematic review of the literature  Journal Articles
• Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma  Journal Articles
• Tocilizumab did not reduce hypoxemic respiratory failure or death in hospitalized patients with COVID-19  Journal Articles
• Tocilizumab versus the Covid19 tempest: All’s well that ends well or much ado about nothing?  Journal Articles
• Transitioning Between Brodalumab and Secukinumab in Moderate to Severe Psoriasis: An Early Look.  Journal Articles
• Trastuzumab Cardiac Side Effects: Only Time Will Tell  Journal Articles
• Treatment of severe facial psoriasis with adalimumab.  Journal Articles
• Treatment with Denosumab Reduces the Incidence of New Vertebral and Hip Fractures in Postmenopausal Women at High Risk  Journal Articles
• Use of lecanemab and donanemab in the Canadian healthcare system: Evidence, challenges, and areas for future research.  Journal Articles
• Using bevacizumab to treat metastatic cancer: UK consensus guidelines  Journal Articles
• Ustekinumab associated thrombotic thrombocytopenic purpura  Journal Articles
• Vedolizumab and Adalimumab in Biologic-Naïve Ulcerative Colitis: Comparison of Patient-Level Clinical Trial Data and VARSITY for Week 6 Clinical Remission  Journal Articles
• Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab  Journal Articles
• When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH  Journal Articles
• [Economic evaluation of bevacizumab versus ranibizumab in neovascular age-related macular degeneration].  Journal Articles
• [Efficacy and safety of natalizumab for multiple sclerosis and Crohn's disease: a meta analysis].  Journal Articles
• ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results  Journal Articles